Published in Endocr Pathol on September 01, 2011
Sorafenib in metastatic thyroid cancer: a systematic review. Oncologist (2014) 1.43
Correlation of immunohistochemical markers and BRAF mutation status with histological variants of papillary thyroid carcinoma in the Korean population. J Korean Med Sci (2013) 0.96
Herpes and polyoma family viruses in thyroid cancer. Oncol Lett (2016) 0.92
miR-219-5p modulates cell growth of papillary thyroid carcinoma by targeting estrogen receptor α. J Clin Endocrinol Metab (2014) 0.91
Combined BRAF(V600E)- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer. Oncotarget (2014) 0.86
Diagnostic and prognostic markers in differentiated thyroid cancer. Curr Genomics (2011) 0.86
The PTTG1-binding factor (PBF/PTTG1IP) regulates p53 activity in thyroid cells. Endocrinology (2014) 0.84
Recurrent thyroid papillary carcinoma in children under ten years old: report of two cases and literature review. Korean J Pathol (2014) 0.82
Family of microRNA-146 Regulates RARβ in Papillary Thyroid Carcinoma. PLoS One (2016) 0.81
Three-dimensional telomere dynamics in follicular thyroid cancer. Thyroid (2013) 0.78
The next generation of orthotopic thyroid cancer models: immunocompetent orthotopic mouse models of BRAF V600E-positive papillary and anaplastic thyroid carcinoma. Thyroid (2014) 0.78
New insights into the diagnosis of nodular goiter. Thyroid Res (2014) 0.77
Extending the Impact of RAC1b Overexpression to Follicular Thyroid Carcinomas. Int J Endocrinol (2016) 0.77
Targeted therapy in rare cancers--adopting the orphans. Nat Rev Clin Oncol (2012) 0.77
[MicroRNA profiles in fine needle biopsy of the thyroid]. Pathologe (2012) 0.76
Preoperative diagnosis of benign thyroid nodules with intermediate cytology. Gland Surg (2012) 0.75
RAC1b overexpression stimulates proliferation and NF-kB-mediated anti-apoptotic signaling in thyroid cancer cells. PLoS One (2017) 0.75
Correlation Between Histological Diagnosis and Mutational Panel Testing of Thyroid Nodules: A Two-Year Institutional Experience. Thyroid (2016) 0.75
Perspectives of the AMP-activated kinase (AMPK) signalling pathway in thyroid cancer. Biosci Rep (2014) 0.75
Simultaneously Detection of 50 Mutations at 20 Sites in the BRAF and RAS Genes by Multiplexed Single-Nucleotide Primer Extension Assay Using Fine-Needle Aspirates of Thyroid Nodules. Yale J Biol Med (2015) 0.75
High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res (2003) 8.67
BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab (2003) 4.93
MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab (2008) 3.40
Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest (2005) 2.77
Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol (2007) 2.75
RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab (2003) 2.72
American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid (2012) 2.71
Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol (2003) 2.67
Contribution of molecular testing to thyroid fine-needle aspiration cytology of "follicular lesion of undetermined significance/atypia of undetermined significance". Cancer Cytopathol (2010) 2.55
Thyroid nodules (≥4 cm): can ultrasound and cytology reliably exclude cancer? World J Surg (2014) 2.40
Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab (2013) 2.34
MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Ann Surg Oncol (2011) 2.25
Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res (2005) 2.23
The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab (2013) 2.17
Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol (2006) 2.15
Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Lett (2004) 2.00
Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene (2005) 1.99
Molecular diagnostics and predictors in thyroid cancer. Thyroid (2009) 1.98
BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer. Ann Surg Oncol (2012) 1.90
RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology (2006) 1.85
Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn (2008) 1.80
Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery (2009) 1.72
PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol (2002) 1.70
Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab (2004) 1.56
Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J Clin Endocrinol Metab (2006) 1.39
Prevalence of RET/PTC rearrangements in Hashimoto's thyroiditis and papillary thyroid carcinomas. Int J Surg Pathol (2002) 1.33
RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact. J Clin Endocrinol Metab (2009) 1.32
Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. Proc Natl Acad Sci U S A (2014) 1.32
Increasing incidence of thyroid cancer: controversies explored. Nat Rev Endocrinol (2013) 1.31
Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation. Clin Cancer Res (2006) 1.27
MicroRNA expression profiles in thyroid tumors. Endocr Pathol (2009) 1.27
Dose-dependent generation of RET/PTC in human thyroid cells after in vitro exposure to gamma-radiation: a model of carcinogenic chromosomal rearrangement induced by ionizing radiation. J Clin Endocrinol Metab (2005) 1.24
Cost impact of molecular testing for indeterminate thyroid nodule fine-needle aspiration biopsies. J Clin Endocrinol Metab (2012) 1.24
RAS mutations in thyroid FNA specimens are highly predictive of predominantly low-risk follicular-pattern cancers. J Clin Endocrinol Metab (2013) 1.22
Proliferative activity of human thyroid cells in various age groups and its correlation with the risk of thyroid cancer after radiation exposure. J Clin Endocrinol Metab (2006) 1.22
A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer (2011) 1.21
Downregulation of Rap1GAP through epigenetic silencing and loss of heterozygosity promotes invasion and progression of thyroid tumors. Cancer Res (2010) 1.21
Molecular and histopathologic characteristics of multifocal papillary thyroid carcinoma. Am J Surg Pathol (2013) 1.19
ETV6-NTRK3 is a common chromosomal rearrangement in radiation-associated thyroid cancer. Cancer (2013) 1.18
MicroRNA expression array identifies novel diagnostic markers for conventional and oncocytic follicular thyroid carcinomas. J Clin Endocrinol Metab (2012) 1.11
Detection of IDH1 and IDH2 mutations by fluorescence melting curve analysis as a diagnostic tool for brain biopsies. J Mol Diagn (2010) 1.10
Pulmonary Langerhans cell histiocytosis: profiling of multifocal tumors using next-generation sequencing identifies concordant occurrence of BRAF V600E mutations. Chest (2013) 1.09
Mechanisms of chromosomal rearrangements in solid tumors: the model of papillary thyroid carcinoma. Mol Cell Endocrinol (2009) 1.06
Both BRAF V600E mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid cancer. Ann Surg Oncol (2011) 1.04
RET/PTC and PAX8/PPARγ chromosomal rearrangements in post-Chernobyl thyroid cancer and their association with iodine-131 radiation dose and other characteristics. Cancer (2013) 1.04
BRAF mutation detection in indeterminate thyroid cytology specimens: underlying cytologic, molecular, and pathologic characteristics of papillary thyroid carcinoma. Cancer Cytopathol (2012) 1.04
Comprehensive MicroRNA expression profiling identifies novel markers in follicular variant of papillary thyroid carcinoma. Thyroid (2013) 1.02
Homologous chromosomes make contact at the sites of double-strand breaks in genes in somatic G0/G1-phase human cells. Proc Natl Acad Sci U S A (2012) 1.02
A clinical algorithm for fine-needle aspiration molecular testing effectively guides the appropriate extent of initial thyroidectomy. Ann Surg (2014) 0.99
Tumor-to-tumor metastases to follicular variant of papillary thyroid carcinoma: histologic, immunohistochemical, and molecular studies of two unusual cases. Endocr Pathol (2009) 0.98
Alterations of the BRAF gene in thyroid tumors. Endocr Pathol (2005) 0.97
Diagnosis and management of differentiated thyroid cancer using molecular biology. Laryngoscope (2013) 0.97
BRAF copy number gains in thyroid tumors detected by fluorescence in situ hybridization. Endocr Pathol (2005) 0.97
Thyroid nodules with KRAS mutations are different from nodules with NRAS and HRAS mutations with regard to cytopathologic and histopathologic outcome characteristics. Cancer Cytopathol (2014) 0.96
RAS mutation-positive follicular variant of papillary thyroid carcinoma arising in a struma ovarii. Endocr Pathol (2010) 0.95
Suspicious ultrasound characteristics predict BRAF V600E-positive papillary thyroid carcinoma. Thyroid (2012) 0.94
Is ionizing radiation responsible for the increasing incidence of thyroid cancer? Cancer (2010) 0.93
Cytomorphological and molecular genetic findings in pediatric thyroid fine-needle aspiration. Cancer Cytopathol (2012) 0.93
Nodule size is an independent predictor of malignancy in mutation-negative nodules with follicular lesion of undetermined significance cytology. Surgery (2013) 0.91
Utilization of ancillary studies in thyroid fine needle aspirates: a synopsis of the National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference. Diagn Cytopathol (2008) 0.90
Summary statement: utility of molecular marker testing in thyroid cancer. Surgery (2010) 0.90
Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells. Cancer Res (2004) 0.89
HOOK3-RET: a novel type of RET/PTC rearrangement in papillary thyroid carcinoma. Endocr Relat Cancer (2007) 0.89
Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group. Pediatr Blood Cancer (2010) 0.88
Knockdown of IG20 gene expression renders thyroid cancer cells susceptible to apoptosis. J Clin Endocrinol Metab (2009) 0.88
MicroRNA profile of poorly differentiated thyroid carcinomas: new diagnostic and prognostic insights. J Mol Endocrinol (2014) 0.88
Formation of carcinogenic chromosomal rearrangements in human thyroid cells after induction of double-strand DNA breaks by restriction endonucleases. Endocr Relat Cancer (2012) 0.86
Gene position within chromosome territories correlates with their involvement in distinct rearrangement types in thyroid cancer cells. Genes Chromosomes Cancer (2009) 0.86
PAX8/PPARγ rearrangement in thyroid nodules predicts follicular-pattern carcinomas, in particular the encapsulated follicular variant of papillary carcinoma. Thyroid (2014) 0.86
Molecular profile of hyalinizing trabecular tumours of the thyroid: high prevalence of RET/PTC rearrangements and absence of B-raf and N-ras point mutations. Eur J Cancer (2005) 0.85
RET/PTC Rearrangement--a link between Hashimoto's thyroiditis and thyroid cancer...or not. J Clin Endocrinol Metab (2006) 0.85
Homologous chromosomes move and rapidly initiate contact at the sites of double-strand breaks in genes in G₀-phase human cells. Cell Cycle (2013) 0.85
MicroRNA dysregulation in human thyroid cells following exposure to ionizing radiation. Thyroid (2011) 0.84
Use of molecular biomarkers in FNA specimens to personalize treatment for thyroid surgery. Head Neck (2012) 0.84
Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients. Ann Surg (2015) 0.81
RET rearrangements in lung adenocarcinoma and radiation. J Thorac Oncol (2014) 0.81
Next-Generation Sequencing Informatics: Challenges and Strategies for Implementation in a Clinical Environment. Arch Pathol Lab Med (2016) 0.81
Amiodarone-induced thyrotoxicosis and thyroid cancer: clinical, immunohistochemical, and molecular genetic studies of a case and review of the literature. Arch Pathol Lab Med (2004) 0.80
Frequency of close positioning of chromosomal loci detected by FRET correlates with their participation in carcinogenic rearrangements in human cells. Genes Chromosomes Cancer (2012) 0.80
Loss of heterozygosity of selected tumor suppressor genes in parathyroid carcinoma. Surgery (2008) 0.80
Establishment of a non-tumorigenic papillary thyroid cell line (FB-2) carrying the RET/PTC1 rearrangement. Int J Cancer (2002) 0.80
Intraoperative pathologic examination in the era of molecular testing for differentiated thyroid cancer. J Am Coll Surg (2012) 0.79
Suitability of animal models for studying radiation-induced thyroid cancer in humans: evidence from nuclear architecture. Thyroid (2011) 0.79
Editorial: anaplastic carcinoma of the thyroid--will aurora B light a path for treatment? J Clin Endocrinol Metab (2005) 0.79
Isozyme-specific abnormalities of PKC in thyroid cancer: evidence for post-transcriptional changes in PKC epsilon. J Clin Endocrinol Metab (2002) 0.79
Preoperative cytology with molecular analysis to help guide surgery for pediatric thyroid nodules. Int J Pediatr Otorhinolaryngol (2013) 0.79
DNA topoisomerases participate in fragility of the oncogene RET. PLoS One (2013) 0.79
BRAF kinase activation via chromosomal rearrangement in radiation-induced and sporadic thyroid cancer. Cell Cycle (2005) 0.78
Follicular variant papillary thyroid carcinoma arising within an ovarian teratoma. Thyroid (2007) 0.77
Multiple focal nodular hyperplasia of the liver in a 21-year-old woman. J Gastrointest Surg (2004) 0.77
Detection of SYT-SSX rearrangements in synovial sarcomas by real-time one-step RT-PCR. Pediatr Dev Pathol (2005) 0.76
Neoadjuvant treatment of unresectable medullary thyroid cancer with sunitinib. J Clin Oncol (2010) 0.76
Encapsulated papillary oncocytic neoplasms of the thyroid: morphologic, immunohistochemical, and molecular analysis of 18 cases. Am J Surg Pathol (2010) 0.76
Thyroid carcinoma-associated genetic mutations also occur in thyroid lymphomas. Mod Pathol (2012) 0.75
Clinical and Morphologic Features of ETV6-NTRK3 Translocated Papillary Thyroid Carcinoma in an Adult Population Without Radiation Exposure. Am J Surg Pathol (2017) 0.75
ROLE OF MOLECULAR MARKERS IN THYROID NODULE MANAGEMENT: THEN AND NOW. Endocr Pract (2017) 0.75
Template for Reporting Results of Biomarker Testing of Specimens From Patients With Thyroid Carcinoma. Arch Pathol Lab Med (2016) 0.75
Autonomously functioning thyroid nodules are not associated with BRAF mutations. Clin Endocrinol (Oxf) (2004) 0.75
Characterizing Molecular Variants and Clinical Utilization of Next-generation Sequencing in Advanced Breast Cancer. Appl Immunohistochem Mol Morphol (2016) 0.75